Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Colloquium supported by Eli Lilly and Company: Integrating molecular oncology in the care of patients with rare oncogene-driven non-small cell lung cancer

The importance of next-generation sequencing (NGS) testing in non-small cell lung cancer: Science, implementation and timing

Date

22 Oct 2023

Session

ESMO Colloquium supported by Eli Lilly and Company: Integrating molecular oncology in the care of patients with rare oncogene-driven non-small cell lung cancer

Topics

Pathology/Molecular Biology;  Translational Research;  Molecular Oncology

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Albrecht Stenzinger

Authors

A. Stenzinger

Author affiliations

  • Institute Of Pathology, University Hospital Heidelberg, Institute of Pathology, 69120 - Heidelberg/DE

Resources

This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.